FDA Grants AP Status for Lenalidomide ANDA210480 by Alvogen
The FDA has granted Abbreviated Approval (AP) status for Alvogen's ANDA210480 for lenalidomide.
Published: July 31, 2026
Updated: July 31, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Small Molecule
Asset: Alvogen
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Alvogen
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's grant of Abbreviated Approval status for Alvogen's generic lenalidomide introduces significant competition in the oncology market. This could impact pricing and market share for existing branded therapies, necessitating strategic adjustments by pharma companies with similar products.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor Alvogen's launch timeline and market uptake of the generic lenalidomide.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.